Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Adamis Pharmaceuticals : Announces Receipt of Deficiency Letter from Nasdaq (Form 8-K)

06/01/2021 | 04:39pm EDT

Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from Nasdaq

SAN DIEGO - May 28, 2021 - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the 'Company'), today announced that, as expected, on May 25, 2021, it received a standard notification letter (the 'Notice') from the Listing Qualifications Department of The Nasdaq Stock Market LLC ('NASDAQ') notifying the Company that, because the Company did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the 'Filing' or the 'Form 10-Q'), the Company is no longer in compliance with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission (the 'SEC').

The Notice also indicated that the Company has 60 calendar days to submit a plan to regain compliance and, if NASDAQ accepts the plan, NASDAQ can grant an exception of up to 180 calendar days from the Filing's due date to regain compliance. The Company may regain compliance at any time during this 180-day period upon filing with the SEC its Form 10-Q, as well as all subsequent required periodic financial reports that are due within that period. If NASDAQ does not accept the Company's plan, the Company will have the opportunity to appeal that decision to a NASDAQ Hearings Panel. The Notice was issued in accordance with standard NASDAQ procedures and has no immediate effect on the listing of the Company's common stock on the NASDAQ Capital Market.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose, is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, USC, compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com.

Adamis Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements with respect to the expected timing for the filing of the Form 10-Q and our ability to regain compliance with the NASDAQ continued listing standards. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including those related to our ability to file the Form 10-Q before the time period specified in the Notice and our ability to regain compliance with the NASDAQ continued listing standards. These factors, together with those that are described in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020, and our subsequent filings with the SEC, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Contact:

Adamis Investor Relations

Robert Uhl

Managing Director

Westwicke ICR

619.228.5886

robert.uhl@westwicke.com

Disclaimer

Adamis Pharmaceuticals Corporation published this content on 01 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 June 2021 20:38:01 UTC.


ę Publicnow 2021
All news about ADAMIS PHARMACEUTICALS CORPORATION
08/04ADAMIS PHARMACEUTICALS : Announces Agreement to Sell Portion of US Compounding B..
AQ
07/19ADAMIS PHARMACEUTICALS CORP : Submission of Matters to a Vote of Security Holder..
AQ
07/19ADAMIS PHARMACEUTICALS : Announces Results of 2021 Annual Meeting of Stockholder..
BU
07/19Declaration of Voting Results by Adamis Pharmaceuticals
CI
07/14ADAMIS PHARMACEUTICALS : Urges Stockholders to Vote to Reelect the Company's Boa..
AQ
07/13Adamis Pharmaceuticals Solicits Proxies from Shareholders
CI
07/13ADAMIS PHARMACEUTICALS : Urges Stockholders to Vote to Reelect the Company's Boa..
BU
07/13ADAMIS PHARMACEUTICALS CORP : Regulation FD Disclosure, Financial Statements and..
AQ
07/02ADAMIS PHARMACEUTICALS : Sends Letter to Stockholders to Address Jerald A. Hamma..
AQ
07/01ADAMIS PHARMACEUTICALS : áAdamis Sends Letter to Stockholders to Address Jerald ..
BU
More news
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,06x
Yield 2021 -
Capitalization 153 M 153 M -
Capi. / Sales 2021 6,97x
Capi. / Sales 2022 15,3x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 1,03 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
Robert O. Hopkins Chief Financial Officer & Secretary
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION112.33%153
JOHNSON & JOHNSON10.15%456 367
ROCHE HOLDING AG14.56%340 460
PFIZER, INC.22.77%252 960
ELI LILLY AND COMPANY55.45%237 950
NOVARTIS AG-0.36%223 613